Current share price for PME : $107.210 3.11 (2.99%)
Pro Medicus Limited (PME), an ASX-listed company, is the development and supply of healthcare imaging software, Radiology Information System (RIS) software and services to hospitals, diagnostic imaging groups and other related health entities in Australia, North America and Europe.
ASX Code | PME |
Website | http://www.promed.com.au |
Industry/Sector | Health Care Technology |
Market Cap ($M) | 11,195 |
PME Share Price | $107.210 |
Day High | $107.210 |
Day Low | $104.210 |
Last Close | $104.100 |
PME Share Price Movement | $3.11 ( 2.99% ) |
Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
---|---|---|---|---|---|---|---|
Result | 18¢ | 100% | 29 Feb 2024 | 22 Mar 2024 | $107.210 | $106.350 | 0.34% |
HFResult | 17¢ | 100% | 6 Sep 2023 | 28 Sep 2023 | $107.210 | $106.350 | 0.34% |
Result | 13¢ | 100% | 2 Mar 2023 | 24 Mar 2023 | $107.210 | $106.350 | 0.34% |
See all dividends from Pro Medicus Limited (PME) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
---|---|---|---|---|---|
Notification of buy-back - PME | 2 Apr 2024 8:35AM | $103.750 | $107.210 | $106.350 | risen by 3.33% |
Update - Notification of buy-back - PME | 2 Apr 2024 8:33AM | $103.750 | $107.210 | $106.350 | risen by 3.33% |
S&P DJI Announces March 2024 Quarterly Rebalance | 1 Mar 2024 5:03PM | $103.390 | $107.210 | $106.350 | risen by 3.69% |
See all ASX announcements from Pro Medicus Limited (PME) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
---|---|---|---|---|---|---|---|
2025F | $93.90 | $89.83 | 19.20% | 115.89 | 45.00 | 0.43% | 100.0% |
2024F | $78.76 | $75.35 | 29.70% | 138.16 | 38.00 | 0.37% | 100.0% |
2023A | $60.77 | $58.11 | 36.80% | 99.61 | 30.00 | 0.52% | 100.0% |
Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | ||
Pro Medicus (PME) | $10,871M | 0.3647 | 0.2997 | 0.2559 | 179.4828 | 138.1003 | 109.9609 | 0.29% | 0.36% | 0.42% |
Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
---|---|---|---|---|
Company | 3.00 | 148.50 | 80.70 | 5.35 |
Market | 0.40 | 15.10 | 1.10 | 1.04 |
Sector | 0.89 | 31.90 | 2.45 | 2.45 |
Name | Position | Start Date |
---|---|---|
Dr Sam Aaron Hupert | Chief Executive Officer, Managing Director | 1 Jan 1983 |
Mr Anthony Barry Hall | Executive Director, Technology Director | 1 Jan 1983 |
Mr Peter Terence Kempen | Non-Executive Chairman, Non-Executive Director | 12 Mar 2008 |
Ms Alice Joan Morrice Williams | Non-Executive Director | 1 Sep 2021 |
Ms Deena Robyn Shiff | Non-Executive Director | 1 Aug 2020 |
Mr Anthony James Glenning | Non-Executive Director | 1 May 2016 |
Dr Leigh Bernard Farrell | Non-Executive Director | 8 Sep 2017 |
Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
---|---|---|---|---|---|---|
21 Feb 2024 | WILLIAMS, Alice | Buy | Direct Shares | 850 | $87.860 | $74,681.000 |
16 Feb 2024 | WILLIAMS, Alice | Buy | Indirect Shares | 810 | $89.970 | $72,875.700 |
27 Nov 2023 | WILLIAMS, Alice | Buy | Direct Shares | 250 | $90.040 | $22,510.000 |
See all changes in directors' interest & trades for Pro Medicus Limited (PME) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
Name | Position |
---|---|
Clayton Hatch | Chief Financial Officer |
Nick Peace | Chief Strategy Officer |
Danny English | Company Secretary |
Danny Tauber | General Manager Australia |
Malte Westerhoff | General Manager Europe and Global Chief Technology Officer |
Brad Levin | General Manager North America and Global Head of Marketing |
Teresa Gschwind | Global Head of Customer Service |
Sean Lambright | Global Head of Sales |
Sharni Redenbach | People and Culture Director |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Pro Medicus Limited (PME). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
Holding | Name |
---|---|
26,137,660 (25.03%) | Sam Aaron Hupert |
26,109,000 (25%) | Hall, Anthony Barry |
Date | Event |
---|---|
13 February 2025 | Report (Interim) |
13 August 2024 | Report (Annual) |
13 August 2024 | Report (Prelim) |
Pro Medicus Limited's (PME) current share price is $107.21. This constitutes a price movement of 0.81% when compared to the share price 7 days ago and is -3.72% below PME's 12-month high of $111.35 per share. Prices are delayed by at least 20 minutes.
Relative to the previous close share price of $104.10, Pro Medicus Limited's (PME) current share price of $107.21 constitutes a movement of $3.11 or 2.99%. Pro Medicus Limited's (PME) share price movement is 0.81% when compared to 7 days ago and is -3.72% below PME's 52-week high of $111.35.
Pro Medicus Limited's (PME) 52-week high is $111.35 which was reached on 12 Feb 2024. Relative to this, PME's current share price of $107.21 constitutes a -$4.14 or -3.72% drop since that high of $111.35 per PME share.
Pro Medicus Limited's (PME) 52-week low is $59.35 which was reached on 31 May 2023. Relative to this, PME's current share price of $107.21 constitutes a $47.86 or 80.64% gain since that low of $59.35 per PME share.
Over the last 12 months, Pro Medicus Limited (PME) has a daily average trading volume of 209,333 PME shares per day.
Pro Medicus Limited (PME) has a current dividend yield of n/a this year. Last year's dividend yield was 0.50%. The dividend yield for PME is a ratio that tells you the percentage of Pro Medicus Limited's (PME) share price that it pays out in dividends each year.
Pro Medicus Limited (PME) last dividend payment was $0.18 per share and was paid on 22 Mar 2024. This last PME dividend included 100% franking.
Pro Medicus Limited (PME) has a franking level of 100%. Franking represents the tax Pro Medicus Limited (PME) has already paid on any profit it distributes to shareholders as a dividend.
Pro Medicus Limited (PME) will release its next Annual Report on 13 August 2024. Pro Medicus Limited's (PME) last annual report was released on 15 Aug 2023. Click here to view Pro Medicus Limited's (PME) last annual report.
Pro Medicus Limited (PME) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Cochlear Limited (COH), and Fisher & Paykel Healthcare Corporation Limited (FPH).
The price-to-earnings (P/E) ratio for Pro Medicus Limited (PME) is 148.5. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Pro Medicus Limited's (PME) share price to its earnings per PME share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.